Integrative genetic and liver transcriptomic analyses identify <i>TRIB1AL</i> as a target for steatotic liver disease
These results open the door to liver-targeted therapeutics silencing of the non-coding genome for the prevention and treatment of MASLD and cardiometabolic diseases.
Authors
- Éloi Gagnon (ORCID: https://orcid.org/0000-0002-7483-1371)
- Jérôme Bourgault (ORCID: https://orcid.org/0000-0002-5803-353X)
- Florence Roux‐Dalvai (ORCID: https://orcid.org/0000-0002-9961-8964)
- Mathieu Laplante (ORCID: https://orcid.org/0000-0002-1752-6741)
- Émilie Gobeil (ORCID: https://orcid.org/0000-0002-5365-0731)
- S. Theriault
- Patricia L. Mitchell (ORCID: https://orcid.org/0000-0002-0773-1047)
- Nolwenn Samson (ORCID: https://orcid.org/0000-0002-4615-7762)
- Patrick Mathieu (ORCID: https://orcid.org/0000-0002-3805-2004)
- Alexandre Caron (ORCID: https://orcid.org/0000-0001-6939-6136)
- Clarisse Gotti (ORCID: https://orcid.org/0000-0001-8316-7030)
- Arnaud Droit
- Marie-Claude Vohl
- Fannie Lajeunesse-Trempe
- Yohan Bossé
- Benoit J Arsenault
- Valérie Côté
- André Tchernof
- Louis-Jacques Ruel
Institutions
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Université Laval (CA)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1210/clinem/dgag043
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00